• HOME
  • ABOUT US
    • Corporate Overview
    • CEO Remarks
    • Management Team
    • Corporate Culture
  • NEWS
    • Corporate News
    • Industry News
  • R & D
    • Therapeutic Areas
    • R&D Platforms
    • Research Strategy
    • Product Pipeline
  • CAREERS
    • Our activities
    • Employee Benefits
    • Join Us
  • PARTNERS
    • Our Partners
    • Business Development
    • Investors
  • CONTACTS
中文 | EN
  • 中文 EN
  • HOME
  • ABOUT US

    • Corporate Overview
    • CEO Remarks
    • Management Team
    • Corporate Culture
  • NEWS

    • Corporate News
    • Industry News
  • R & D

    • Therapeutic Areas
    • R&D Platforms
    • Research Strategy
    • Product Pipeline
  • CAREERS

    • Our activities
    • Employee Benefits
    • Join Us
  • PARTNERS

    • Our Partners
    • Business Development
    • Investors
  • CONTACTS
  • About Us

  • Management Team

  • Research Areas

  • R&D Pipeline

  • CAREERS

  • About Us

  • Management Team

  • Research Areas

  • R&D Pipeline

  • CAREERS

February 23 2021

LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

CAMBRIDGE, MA, USA, SEOUL, Korea, and NANJING, China, February 22, 2021 – LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.

View
December 24 2020

TransThera Biosciences Filed the IND Application of TT-00434 to FDA

TransThera Biosciences announces the Investigational New Drug (IND) application of TT-00434 has been submitted to Food and Drug Administration (FDA) in the United States on December 16, 2020. This is the fourth investigational drug developed by the company entering clinical trials.

View
December 18 2020

Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

Tokyo, Japan, and Nanjing, China, December 18, 2020 -- Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group’s healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, jointly announced that they have entered into a strategic collaboration agreement for joint research and development of the innovative drugs in the target fields of oncology and inflammatory diseases.

View
More...

    ABOUT US

  • Corporate Overview
  • CEO Remarks
  • Management Team
  • Corporate Culture

    NEWS

  • Corporate News
  • Industry News

    R & D

  • Therapeutic Areas
  • R&D Platforms
  • Research Strategy
  • Product Pipeline

    CAREERS

  • Our activities
  • Employee Benefits
  • Join Us

    PARTNERS

  • Our Partners
  • Business Development
  • Investors

    CONTACTS

  • CONTACTS
  • Address
General Admin 一般事务:025-86901057/025-86901186
邮箱:info@transtherabio.com
法律声明
Copyright © 2016-2020 All rights reserved. 苏ICP备18052604号